GGrantIndex
← Leaderboards

Peter S Tobias

Scripps Research Institute

$7,403,987
Attributed
$7,403,987
Total exposure
13
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.2M · FY200513
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13

Funding mix

By agency

NIH$7,403,987 · 13

By mechanism

R01$5,404,153 · 5
R21$1,717,381 · 5
P50$230,092 · 1
M01$27,361 · 1
R03$25,000 · 1

Top collaborators

No co-investigators on record.

Most similar at Scripps Research Institute

Same institution · by research overlap

Others in their field

Top investigators on “Inflammation

Research focus

InflammationSignal TransductionInflammatory ResponseProtein Structure FunctionResponseToll-Like ReceptorsReceptorCellsEnzymesEndotoxinsCytokineInfectionPathogenBaseMediatingSterilityHigh Throughput ScreeningLactamaseInhibitor/AntagonistLeadImmune ResponseInjuryScreening ProcedureMediator Of Activation Protein

Grant awards (26)

Abdominal Adipose Tissue Inflammation$225,505
R21 · FY2013 · HL · contact PI
Cellular Activation Mechanisms in Septic Shock$464,322
R01 · FY2012 · AI · contact PI
Cellular Activation Mechanisms in Septic Shock$464,322
R01 · FY2011 · AI · contact PI
Function of microRNA in pro-inflammatory gene expression$455,501
R01 · FY2011 · AI · contact PI
HIGH-THROUGHPUT ASSAYS TO IDENTIFY INHIBITORS OF CARD-CARD INTERACTIONS$235,001
R21 · FY2011 · AI · contact PI
HIGH THROUGHPUT SCREENING FOR TOLL-LIKE RECEPTORS INHIBITORS$469,013
R01 · FY2010 · AI · contact PI
HIGH-THROUGHPUT ASSAYS TO IDENTIFY INHIBITORS OF CARD-CARD INTERACTIONS$284,850
R21 · FY2010 · AI · contact PI
High Throughput Screening Assays to Identify Inhibitors of TLR4 Signaling$189,900
R21 · FY2010 · NS · contact PI
HIGH THROUGHPUT SCREENING FOR TOLL-LIKE RECEPTORS INHIBITORS$473,750
R01 · FY2009 · AI · contact PI
HIGH THROUGHPUT SCREENING FOR TOLL-LIKE RECEPTORS INHIBITORS$379,000
R01 · FY2008 · AI · contact PI
DEFINING INNATE IMMUNE RECEPTOR LIGAND BINDING SITES$525,332
R01 · FY2007 · GM · contact PI
High Throughput Screening for Toll-Like Receptors$25,000
R03 · FY2007 · MH · contact PI
DEFINING INNATE IMMUNE RECEPTOR LIGAND BINDING SITES$525,370
R01 · FY2006 · GM · contact PI
DEFINING INNATE IMMUNE RECEPTOR LIGAND BINDING SITES$522,453
R01 · FY2005 · GM
TLR Signaling and Protein Fragment Complementation$281,550
R21 · FY2005 · AI
DEFINING INNATE IMMUNE RECEPTOR LIGAND BINDING SITES$565,884
R01 · FY2004 · GM
TLR Signaling and Protein Fragment Complementation$234,625
R21 · FY2004 · AI
PATHOPHYSIOLOGY OF LPS-CD14 COMPLEXES$40,863
P50 · FY2002 · HL
GENETICS OF THE ENDOTOXEMIC PHENOMENON$0
M01 · FY2002 · RR
MOLECULAR PATHOLOGY OF LPS HOST PROTEIN COMPLEXES$283,735
R01 · FY2001 · AI
STRUCTURAL CHARACTERIZATION OF INNATE IMMUNITY RECEPTORS$132,975
R21 · FY2001 · GM
PATHOPHYSIOLOGY OF LPS-CD14 COMPLEXES$40,863
P50 · FY2001 · HL
MOLECULAR PATHOLOGY OF LPS HOST PROTEIN COMPLEXES$275,471
R01 · FY2000 · AI
PATHOPHYSIOLOGY OF LPS-CD14 COMPLEXES$148,366
P50 · FY2000 · HL
STRUCTURAL CHARACTERIZATION OF INNATE IMMUNITY RECEPTORS$132,975
R21 · FY2000 · GM
GENETICS OF THE ENDOTOXEMIC PHENOMENON$27,361
M01 · FY2000 · RR